Navigation Links
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Date:9/17/2007

to rapid approval in hypercalcemia. We also foresee the potential for subsequent approvals in other diseases, such as non-Hodgkin's lymphoma, bone metastases, Paget's disease, and osteoporosis. Genta plans to manage the G4544 development program in oncology, and we intend to seek a partner for clinical programs in metabolic bone disease."

Gallium-Containing Compounds

G4544 is one of a class of gallium-containing compounds that were originally developed by the U.S. National Cancer Institute. In investigational studies, high doses of gallium nitrate demonstrated consistent antitumor activity in patients with non-Hodgkin's lymphoma. However, experimental work by Genta personnel and others established that lower doses of gallium directly inhibited calcium release from bone, principally by decreasing bone resorption and possibly by also stimulating bone formation.

Many diseases are associated with accelerated bone loss, including osteoporosis, cancer, and Paget's disease. In some diseases, the rate of loss is slow and subtle, while in others the rate is rapid and acutely life- threatening. In osteoporosis, the most prevalent bone-losing condition, the process of bone loss extends over many years before the disease becomes evident. Conversely, in cancer-related hypercalcemia, bone loss is so rapid that it overwhelms the kidney's ability to eliminate calcium from the blood, and this condition can quickly become lethal. In patients with cancer-related hypercalcemia who were resistant to hydration, randomized double-blind trials have been conducted with Ganite compared with calcitonin and with two bisphosphonates (etidronate [Didronel(R); Proctor and Gamble] and pamidronate [Aredia(R); Novartis, Inc.]).

About G4544

G4544 was developed to enable extended administration of the active ingredient in Ganite, which may greatly improve patient convenience and avoid the current need for intravenous pumps or hospitalization. The initial focus of clinica
'/>"/>

SOURCE Genta Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
7. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
8. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... June 17, 2013 Vanda Pharmaceuticals Inc. ... data today at ENDO 2013, the Endocrine Society,s ... can entrain (synchronize) both melatonin and cortisol rhythms. ... the master body clock and address the circadian ... The SET (Safety and Efficacy of Tasimelteon) and ...
(Date:6/17/2013)... Quebec , June 17, 2013 Valeant Pharmaceuticals ... announced today that it has filed a preliminary prospectus supplement ... has today made a similar filing with securities regulatory authorities ... in connection with a public offering of its common ... "Offering"). The Company will also grant to the ...
(Date:6/17/2013)... NEW YORK , June 17, 2013 The ... and CEO, The Partnership at Drugfree.org :   ... to CNN that it was halting the sale of prescription ... of product we recognize that from time to time there ... are not our customer. As a result of this misinterpretation ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2
... UL, a world leader in advancing ... testing GmbH (MDT) and md registration support Ltd. (MDRS).  These ... UL,s Life and Health business unit.   MDT ... the medical services industry.  MDT specializes in clinical and non-clinical ...
... 2011 Apnex Medical, Inc., received investigational device exemption ... (FDA) to begin a clinical study to evaluate the ... System to treat obstructive sleep apnea (OSA). Data from ... Approval (PMA) application for the HGNS System to the ...
Cached Medicine Technology:UL Expands Presence in Medical Device Market With Acquisition of MDT 2UL Expands Presence in Medical Device Market With Acquisition of MDT 3Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 2Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 3
(Date:6/18/2013)... 2013 Seven-year-old Riley Salz of Encino, ... He receives 40 hours a week of applied behavior ... the Center for Autism and Related Disorders (CARD). Riley ... and has experienced remarkable progress, including learning to speak, ... Riley’s personal journey through autism is now featured in ...
(Date:6/18/2013)... Center clinical researchers have launched an innovative clinical ... the ability of a patient,s own stem cells ... arterial disease (PAD). , Led by Vik ... Hospitals Case Medical Center,s Harrington Heart & Vascular ... Reserve University School of Medicine, the clinical trial ...
(Date:6/18/2013)... More than 1.1 million people in the ... to the Centers for Disease Control and Prevention (CDC). Of ... support of National HIV Testing Day on June 27, Allsup, ... (SSDI) representation, the CDC and other organizations are raising awareness ... reports about 50,000 new HIV infections each year. Along with ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 myCNAjobs announces ... of free downloads, articles, and tips to the Caregiver ... to care for the 10,000+ retiring baby boomers each ... professional caregiver job resources has never been ... CNA job community, recently launched the first-ever free ...
(Date:6/18/2013)... A new $119 million industry is taking ... is redefining the way consumers get their seafood. ... culinary chefs on the Emerald Coast panhandle of Northwest ... and the promising industry of aquaculture. , The word ... strive to fully partake in the effort, especially when ...
Breaking Medicine News(10 mins):Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2Health News:New $119 Million Industry Swimming Up the East Coast 2
... -- Men with low testosterone levels may be at increased ... a finding that challenges the current belief that testosterone is ... The study included 930 men with coronary artery disease ... of the study, low testosterone levels were noted in about ...
... ARBOR, Mich. Millions worldwide die each year because they ... States say they,d be willing to donate theirs after death ... Circulation, experts at the University of Michigan Cardiovascular ... they are removed for burial or cremation, for sterilization and ...
... Reinberg HealthDay Reporter , TUESDAY, Oct. 19 (HealthDay ... mothers and their infants from taking supplemental fish oil in ... finds no such benefit. In this large randomized, ... found no benefit from DHA in reducing levels of postpartum ...
... 19 (HealthDay News) -- Kidney-failure patients can continue taking a ... study showed they can increase the risk of stroke, U.S. ... and Drug Administration advisers voted 15-1, with one abstention, to ... disease who aren,t yet in need of dialysis, the ...
... Medicine investigated the role between adiponectin and leptin in ... issue of Hepatology , suggest that the protein ... of leptin, namely in hepatocellular carcinoma (HCC), and could ... Obesity is on the rise and is associated with ...
... Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of ... company,s spinal cord stem cells in the treatment of ... Emory University in Atlanta, Georgia. The company announced that, ... non-ambulatory patients, the trial,s Safety Monitoring Board has unanimously ...
Cached Medicine News:Health News:Low Testosterone May Raise Risk of Early Death: Study 2Health News:Recycling pacemakers may alleviate burden of heart disease across the globe 2Health News:Recycling pacemakers may alleviate burden of heart disease across the globe 3Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 2Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 3Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 4Health News:FDA Advisers Back Anemia Drugs for Kidney Patients 2Health News:FDA Advisers Back Anemia Drugs for Kidney Patients 3Health News:FDA Advisers Back Anemia Drugs for Kidney Patients 4Health News:Adiponectin shows potential in blocking obesity-related carcinogenesis 2Health News:Neuralstem updates ALS clinical trial progress 2
Directional `E' and `C' test....
9" X 14" translucent plastic may be used with illuminated test cabinet or as a wall chart 20/200 to 20/15....
... The PowerLab/16SP is a high-performance recording unit ... science research applications that require up to ... and isolated tissue studies. The unit is ... to 200 000 samples per second continuously ...
Three Figure Worth Type Test, this test is used for determining diplopia, suppression or fusion in children. Sturdy chrome flashlight comes with red/green glasses. Requires 3 D batteries which are no...
Medicine Products: